YS-363

YS-363 is a potent, selective, and orally bioavailable EGFR inhibitor with IC50 values of 0.96 nM (wild-type) and 0.67 nM (L858R mutant) . It induces G0/G1 cell cycle arrest and apoptosis in vitro and has demonstrated antitumor efficacy in vivo, making it a valuable tool for oncology research targeting EGFR-driven cancers.